Read by QxMD icon Read

Nicolas P Restifo

Qiong J Wang, Zhiya Yu, Kayla Griffith, Ken-ichi Hanada, Nicholas P Restifo, James C Yang
KRAS is one of the most frequently mutated proto-oncogenes in human cancers. The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. The consistency, frequency, and tumor specificity of these "neoantigens" make them attractive therapeutic targets. Recent data associate T cells that target mutated antigens with clinical immunotherapy responses in patients with metastatic melanoma, lung cancer, or cholangiocarcinoma...
March 2016: Cancer Immunology Research
Joseph G Crompton, Madhusudhanan Sukumar, Rahul Roychoudhuri, David Clever, Alena Gros, Robert L Eil, Eric Tran, Ken-Ichi Hanada, Zhiya Yu, Douglas C Palmer, Sid P Kerkar, Ryan D Michalek, Trevor Upham, Anthony Leonardi, Nicolas Acquavella, Ena Wang, Francesco M Marincola, Luca Gattinoni, Pawel Muranski, Mark S Sundrud, Christopher A Klebanoff, Steven A Rosenberg, Douglas T Fearon, Nicholas P Restifo
Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of this potentially curative therapy may be limited by poor persistence of TIL after adoptive transfer. Pharmacologic inhibition of the serine/threonine kinase Akt has recently been shown to promote immunologic memory in virus-specific murine models, but whether this approach enhances features of memory (e.g., long-term persistence) in TIL that are characteristically exhausted and senescent is not established...
January 15, 2015: Cancer Research
Nicolas Acquavella, David Clever, Zhiya Yu, Melody Roelke-Parker, Douglas C Palmer, Liqiang Xi, Holger Pflicke, Yun Ji, Alena Gros, Ken-Ichi Hanada, Ian S Goldlust, Gautam U Mehta, Christopher A Klebanoff, Joseph G Crompton, Madhusudhanan Sukumar, James J Morrow, Zulmarie Franco, Luca Gattinoni, Hui Liu, Ena Wang, Francesco Marincola, David F Stroncek, Chyi-Chia R Lee, Mark Raffeld, Marcus W Bosenberg, Rahul Roychoudhuri, Nicholas P Restifo
Both targeted inhibition of oncogenic driver mutations and immune-based therapies show efficacy in treatment of patients with metastatic cancer, but responses can be either short lived or incompletely effective. Oncogene inhibition can augment the efficacy of immune-based therapy, but mechanisms by which these two interventions might cooperate are incompletely resolved. Using a novel transplantable BRAF(V600E)-mutant murine melanoma model (SB-3123), we explored potential mechanisms of synergy between the selective BRAF(V600E) inhibitor vemurafenib and adoptive cell transfer (ACT)-based immunotherapy...
January 2015: Cancer Immunology Research
Sid P Kerkar, Anthony J Leonardi, Nicolas van Panhuys, Ling Zhang, Zhiya Yu, Joseph G Crompton, Jenny H Pan, Douglas C Palmer, Richard A Morgan, Steven A Rosenberg, Nicholas P Restifo
Engineering CD8⁺ T cells to deliver interleukin 12 (IL-12) to the tumor site can lead to striking improvements in the ability of adoptively transferred T cells to induce the regression of established murine cancers. We have recently shown that IL-12 triggers an acute inflammatory environment that reverses dysfunctional antigen presentation by myeloid-derived cells within tumors and leads to an increase in the infiltration of adoptively transferred antigen-specific CD8⁺ T cells. Here, we find that local delivery of IL-12 increased the expression of Fas within tumor-infiltrating macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSC), and that these changes were abrogated in mice deficient in IL-12-receptor signaling...
July 2013: Molecular Therapy: the Journal of the American Society of Gene Therapy
Christopher A Klebanoff, Nicolas Acquavella, Zhiya Yu, Nicholas P Restifo
Enthusiasm for therapeutic cancer vaccines has been rejuvenated with the recent completion of several large, randomized phase III clinical trials that in some cases have reported an improvement in progression free or overall survival. However, an honest appraisal of their efficacy reveals modest clinical benefit and a frequent requirement for patients with relatively indolent cancers and minimal or no measurable disease. Experience with adoptive cell transfer-based immunotherapies unequivocally establishes that T cells can mediate durable complete responses, even in the setting of advanced metastatic disease...
January 2011: Immunological Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"